227 related articles for article (PubMed ID: 7931280)
1. Neonatal 6-hydroxydopamine and adult SKF 38393 treatments alter dopamine D1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats.
Gong L; Kostrzewa RM; Li C
J Neurochem; 1994 Oct; 63(4):1282-90. PubMed ID: 7931280
[TBL] [Abstract][Full Text] [Related]
2. Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats.
Gong L; Kostrzewa RM; Brus R; Fuller RW; Perry KW
Brain Res Dev Brain Res; 1993 Nov; 76(1):59-65. PubMed ID: 8306431
[TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
4. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
5. Ontogenic homologous supersensitization of dopamine D1 receptors.
Hamdi A; Kostrzewa RM
Eur J Pharmacol; 1991 Oct; 203(1):115-20. PubMed ID: 1839147
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats.
Plech A; Brus R; Kalbfleisch JH; Kostrzewa RM
Psychopharmacology (Berl); 1995 Jun; 119(4):466-73. PubMed ID: 7480527
[TBL] [Abstract][Full Text] [Related]
7. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment.
Brus R; Kostrzewa RM; Perry KW; Fuller RW
J Pharmacol Exp Ther; 1994 Jan; 268(1):231-7. PubMed ID: 8301563
[TBL] [Abstract][Full Text] [Related]
8. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576
[TBL] [Abstract][Full Text] [Related]
9. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats.
Brus R; Kostrzewa RM; Nowak P; Perry KW; Kostrzewa JP
Neurotox Res; 2003; 5(5):329-38. PubMed ID: 14715452
[TBL] [Abstract][Full Text] [Related]
10. Age-dependence of a 6-hydroxydopamine lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats.
Kostrzewa RM; Brus R; Perry KW; Fuller RW
Brain Res Dev Brain Res; 1993 Nov; 76(1):87-93. PubMed ID: 8306435
[TBL] [Abstract][Full Text] [Related]
11. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
12. Postnatal development of striatal dopamine function. II. Effects of neonatal 6-hydroxydopamine treatments on D1 and D2 receptors, adenylate cyclase activity and presynaptic dopamine function.
Broaddus WC; Bennett JP
Brain Res Dev Brain Res; 1990 Mar; 52(1-2):273-7. PubMed ID: 2110042
[TBL] [Abstract][Full Text] [Related]
13. Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats.
Gong L; Kostrzewa RM; Perry KW; Fuller RW
Brain Res Dev Brain Res; 1993 Dec; 76(2):233-8. PubMed ID: 8149589
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
Pollack AE; Wooten GF
Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
[TBL] [Abstract][Full Text] [Related]
16. Sustained extracellular signal-regulated kinase 1/2 phosphorylation in neonate 6-hydroxydopamine-lesioned rats after repeated D1-dopamine receptor agonist administration: implications for NMDA receptor involvement.
Papadeas ST; Blake BL; Knapp DJ; Breese GR
J Neurosci; 2004 Jun; 24(26):5863-76. PubMed ID: 15229233
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation.
Thomas KL; Rose S; Jenner P; Marsden CD
Biochem Pharmacol; 1992 Jul; 44(1):73-82. PubMed ID: 1321630
[TBL] [Abstract][Full Text] [Related]
18. Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels.
Nowak P; Dabrowska J; Bortel A; Biedka I; Szczerbak G; Słomian G; Kostrzewa RM; Brus R
Eur J Pharmacol; 2006 Dec; 552(1-3):46-54. PubMed ID: 17055481
[TBL] [Abstract][Full Text] [Related]
19. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats.
Criswell H; Mueller RA; Breese GR
J Neurosci; 1989 Jan; 9(1):125-33. PubMed ID: 2521511
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat.
Gresch PJ; Walker PD
Brain Res Mol Brain Res; 1999 Jun; 70(1):125-34. PubMed ID: 10381550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
